Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation.

ABSTRACT:

Objective

To compare the effect on health outcomes of continuing or discontinuing oral anticoagulants (OACs) among patients with unprovoked venous thromboembolism (VTE) after initial treatment for at least 90 days.

Design

Target trial emulation.

Setting

Optum Clinformatics Data Mart (Optum CDM) from 1 January 2009 to 28 Februray 2025, and Medicare fee-for-service claims from 1 January 2009 to 31 December 2022, United States.

Participants

Adults with VTE aged ≥18 years (Optum CDM) or ≥65 years (Medicare) initiating OACs (warfarin or direct OACs) within 30 days after a first hospital admission with VTE without reversible provoking factors and who continued treatment for ≥90 days. Propensity score one-to-one matching was performed between patients who continued an

SUBMITTER: Lin KJ 

PROVIDER: S-EPMC12607009 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature